Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationCurrent Price
as of Oct 16, 2024$32.37
P/E Ratio
N/A
Market Cap
$1.65B
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
Overview
Trading Information
Company